Research programme: atherosclerosis therapy - Digital Gene Technologies/Recordati
Alternative Names: Atherosclerosis therapy research programme - Digital Gene Technologies/RecordatiLatest Information Update: 03 Oct 2005
At a glance
- Originator Digital Gene Technologies; Recordati
- Developer Digital Gene Technologies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 03 Oct 2005 Discontinued - Preclinical for Hypercholesterolaemia in USA (unspecified route)
- 03 Nov 2003 Suspended - Preclinical for Hypercholesterolaemia in USA (unspecified route)
- 15 Feb 2001 New profile